Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization
Open Access
- 10 February 2026
- journal article
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 11 (1)
Abstract
Objectives: We evaluated the impact of teprotumumab therapy ( TT ) introduction on orbital decompression ( OD ) utilization for thyroid eye disease ( TED ) and compared rates of significant exophthalmos reduction ( SER ) and diplopia between TT and OD . Methods: Newly diagnosed TED patients treated pre (2015–2020) and post teprotumumab (2020–2025) FDA approval were identified from the EHR . Utilization trends, diplopia rates, and immediate (≤ 6 weeks post‐intervention) and long‐term follow‐up SER (≥ 2 mm reduction) were studied. Results: Of 406 TED patients, 53 (36.8%) underwent OD in the pre‐ TT cohort ( n = 144). Post‐teprotumumab approval ( n = 262), primary OD was performed in 29 (11.1%), of which 3 (10.3%) were subsequently placed on TT ; primary TT was used in 68/262 (25.9%) with subsequent OD performed in 9 (13.2%). The remaining patients used other treatments (corticosteroids, orbital radiation, rituximab, tocilizumab, etc.). In the overall cohort, immediate SER was achieved in 94.4% of OD versus 83.8% of TT patients ( p = 0.028), with greater median reduction in the OD group (5 vs. 4 mm; p = 0.001). At long‐term follow‐up (median 13 vs. 12 months), SER was sustained in 85.4% of OD and 62.9% of TT patients ( p = 0.042). Pre‐therapy diplopia was more prevalent in TT vs. OD patients (79.4% vs. 59.7%; p = 0.019). New‐onset posttreatment diplopia was higher in the OD group (20.7% vs. 5.9%; p = 0.008). Conclusions: Rates of OD surgery declined following FDA approval of teprotumumab. OD achieved sustained and greater exophthalmos reduction but carried a higher risk of diplopia. Contemporaneous OD indications may have evolved to use in TT‐recalcitrant TED or those in need of urgent decompression. Level of Evidence: 4.Keywords
This publication has 24 references indexed in Scilit:
- Teprotumumab for the Treatment of Active Thyroid Eye DiseaseNew England Journal of Medicine, 2020
- Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statementOrphanet Journal of Rare Diseases, 2017
- Smoking and thyroidClinical Endocrinology, 2013
- Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye DiseaseEuropean Thyroid Journal, 2012
- A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathyJournal of Molecular Endocrinology, 2011
- Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GOEuropean Journal of Endocrinology, 2008
- Biological Effects of Thyrotropin Receptor Activation on Human Orbital PreadipocytesInvestigative Ophthalmology & Visual Science, 2006
- Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathyBritish Journal of Ophthalmology, 2005
- Clinical activity score as a guide in the management of patients with Graves' ophthalmopathyClinical Endocrinology, 1997
- Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.British Journal of Ophthalmology, 1989